

Steps to graduating

- Scheduling defense
- Obtaining warrant
- Reserve time/room
- Announcement or flyer to Debbie and Sally
- Writing dissertation- to committee in advance 2 weeks
- Final defense (public presentation then committee only)
- Deposit dissertation (with committee changes, if relevant) along with surveys

>> If you are completely finishing in middle of semester, need to do grading for 990 and 931/932

>> International students should check with ISS if they have VISA or other concerns/questions

Dates

- Degrees are only conferred at end of each semester
- Can get degree completion letter: <https://grad.wisc.edu/documents/certification-of-graduation/>
- See this page for deadlines: <https://grad.wisc.edu/wp-content/uploads/sites/329/2023/08/Graduate-School-Degree-Deadlines-2023-2024.pdf>
- What are window periods? Between end of one and start of next semester- can defend/deposit and not register for next semester- but official degree conferral at end of next semester
- See also: <https://grad.wisc.edu/documents/degree-conferral-payroll-end-dates/>

Overall grad school policy

<https://policy.wisc.edu/library/UW-1248>

- **Dissertations**

- A doctoral dissertation must be a dissertator's own work. If it is the result of research enterprises in which others have collaborated, a substantial portion must represent the dissertator's own contribution and the other **research participants must be identified**.
- Dissertations must include **acknowledgement of contributions received from other individuals, including co-authors of published work that appears in the document**. This includes those who contributed in designing the research, executing the research, analyzing the data, interpreting the data/research, or writing, proofing, or copyediting the manuscript.
- **Publication of the doctoral dissertation is required**. ProQuest UMI ETD Administrator is used to publish the dissertation electronically and on microfilm, and to publish an abstract of the dissertation in Dissertation Abstracts, a monthly publication. Dissertators must pay the cost of processing the dissertation and publishing the abstract by ProQuest.

Example contribution acknowledgement (Cassie Lew)

Chapter 3. Proteomic Correlates of Enhanced Daptomycin Activity with β -Lactam Pre-Conditioning

Authors and their contributions:

Cassandra Lew: Planned and conducted experiments, wrote and edited manuscript

Molly Pellitteri Hahn: Planned and conducted proteomics experiments

Cameron Scarlett: Contributed to design of proteomics experiments

Aaron Rottier: Contributed to design of activity experiments

Andrew D Berti: Contributed to design of activity experiments

Richard A Proctor: Contributed intellectual input

Arnold S Bayer: Supervised research and contributed to design of experiments

Warren E Rose: Supervised research and contributed to design of experiments

Portions of this chapter have been previously published as:

Lew C, Pellitteri Hahn M, Scarlett C, Rottier A, Berti AD, Proctor RA, Bayer AS, Rose WE. 2022. Proteomic Correlates of Enhanced Daptomycin Activity Following β -Lactam Pre-Conditioning in Daptomycin-Resistant Methicillin-Resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 66(3)

Formatting

<https://grad.wisc.edu/current-students/doctoral-guide/#defend-and-deposit-your-dissertation>

- Your dissertation is required to conform to these standards. It will be fully corrected, complete, and submitted electronically as a single PDF file.
- Keep in mind that the formatting must be consistent throughout the dissertation with the exception of the Appendix. Previously published articles can be placed in the Appendix in their published format. If previously published work is included in a chapter, its format must conform to the formatting guidelines.
- Dissertations must acknowledge contributions from other individuals, including co-authors of published material that appears in the document, such as designing the research, executing the research, analyzing the data, interpreting the research/data, or writing, proofing, copyediting the manuscript. Contributions can be recognized in an acknowledgements section or at the beginning of a chapter where the contributed material is used.

Formatting

<https://grad.wisc.edu/current-students/doctoral-guide/#defend-and-deposit-your-dissertation>

+ Appendices
+ Bibliography
+ Equations, superscripts, and subscripts
+ Footnotes and endnotes
+ Graphics
+ Language use
+ Margins
+ Page numbering
+ Production of document
+ Title page
+ Additional guidelines
+ Embargo/delayed release

Formatting

<https://grad.wisc.edu/current-students/doctoral-guide/#defend-and-deposit-your-dissertation>

- See this document for details, including fonts, title page etc.:
<https://grad.wisc.edu/wp-content/uploads/sites/329/2023/04/Formatting-Requirements-for-your-Doctoral-Dissertation.pdf>
- To request a pre-check, you may email a PDF of your entire dissertation to degree coordinator alexandra.walter@wisc.edu. If you would prefer to meet in person, email alexandra.walter@wisc.edu to arrange a time.

How to find examples

- <https://www.library.wisc.edu/find/dissertations/>
- Recommend using the Proquest option
- Some recent ones may still be under embargo (talk to your advisor about if you should do this!)
- Can use pharmaceutical sciences as key word

General outline

- 1) "Preliminary pages"- Acknowledgements, Abstract, Table of contents, others may be there (dedication, list of abbreviations, list of figures/tables), copyright page if desired
- 2) Introduction/summary chapter
- 3) Data chapters
- 4) Conclusions/future direction chapter
- 5) (Optional) appendix

Example: Xin Yao

Table of Contents

Acknowledgements	ii
Abstract	viii
Chapter 1. Introduction	1
1.1. Overview	2
1.2. Crystal Nucleation	4
1.3. Polymorphism	13
1.4. Anisotropic Environment at the Surface and the Impact on Crystallization	16
1.5. Effect of a Second Component on Crystal Nucleation and Growth	17
1.6. Contributions of This Thesis	19
1.7. References	22
Chapter 2. Anisotropic Molecular Organization at a Liquid/Vapor Interface Promotes Crystal Nucleation with Polymorph Selection	28
2.1. Abstract	29
2.2. Introduction	29
2.3. Results and Discussion	30
2.4. Conclusions	42
2.5. Materials and Methods	43
2.6. Acknowledgements	47
2.7. Supporting Information	47
2.8. References	54

Example: Xin Yao

Chapter 7. Amorphous Drug–Polymer Salts.....	169
7.1. Abstract	170
7.2. Introduction.....	170
7.3. Polyelectrolyte Coating.....	174
7.4. Amorphous Drug–Polymer Salts in the Bulk.....	180
7.5. Concluding Remarks.....	187
7.6. Acknowledgments.....	189
7.7. References.....	189
Chapter 8. Conclusions and Future Work.....	194
8.1. Surface Nucleation in Different Molecular Liquids.....	195
8.2. Effect of Dopants on Surface Nucleation.....	199
8.3. Effects of Molecular Weight, Drug Loading, and Synthesis Process on the Protonation Ratio and Performance of Amorphous Drug-Polymer Salts	200
8.4. References.....	201

Example: Pawel Zbyszynski

Table of Contents

Abstract	i
Acknowledgments	iii
Table of Contents	vi
List of Tables	x
List of Figures	xi
List of Abbreviations	xx
Chapter 1: Fibronectin Matrix Assembly is a Rational Target For Fibrosis Therapy	1
1.1 Introduction	2
1.2 The Structurally and Functionally Complex Fibronectin	2
1.2.1 The Structure of Fibronectin	2
1.2.2 Fibronectin Fibril Assembly	5
1.2.3 Fibronectin Fibrillogenesis Inhibition	7
1.3 Fibronectin is an Active Participant in Fibrosis Progression	8
1.3.1 Fibronectin Has a Functional Role in Collagen Fiber Deposition	8
1.3.2 Fibronectin Assists in Tissue Infiltration and Activation of Fibroblasts	9
1.3.3 Fibronectin and TGF- β Activation	10
1.3.4 Fibronectin Assists Collagen Fiber Maturation via LOX Activation	12
1.3.5 Fibronectin Promotes Leukocyte Tissue Infiltration	12
1.4 <i>In Vivo</i> Application of Fibronectin Matrix Assembly	13
1.4.1 FN Matrix Assembly Inhibition: Vascular Remodeling Pathology	14
1.4.2 FN Matrix Assembly Inhibition: Cardiac Fibrosis	14
1.4.3 FN Matrix Assembly Inhibition: Liver Fibrosis	15
1.4.4 Unexplored Application of FN Matrix Assembly Inhibition: Renal Fibrosis	16

Example: Pawel Zbyszynski

1.5 Research Proposal	18
1.5.1 Rationale	18
1.5.2 Objectives	20
1.5.3 Specific Aims	20
Chapter 2: Characterization of the PEGylated Functional Upstream Domain Peptide (PEG-FUD): a Potent Fibronectin Assembly Inhibitor with Potential as an Anti- fibrotic Therapeutic	22
2.1 Introduction	23
<hr/>	
2.2 Materials	25
2.3 Procedure	26
2.3.1 FUD and mFUD Synthesis	26
2.3.2 Preparation of PEGylated FUD and mFUD	27
2.3.3 FPLC Separation and Purification of PEGylated FUD and mFUD	28
2.3.4 GPC Characterization	28
2.3.5 HPLC Characterization	28
2.3.6 MALDI-TOF Characterization of PEG-FUD	29
2.3.7 ITC Characterization	29
2.3.8 Matrix Assembly Assay	29

Example: Pawel Zbyszynski

2.4 Results	30
2.4.1 PEG-FUD Synthesis	30
2.4.2 PEG-FUD Characterization	33
2.4.3 PEG-FUD Binding Studies	38
2.5 Discussion	43
2.6 Conclusion	46
2.7 Acknowledgments and Disclosures	46
2.8 Supporting Information	48
Chapter 3: PEGylated pUR4/FUD Peptide Inhibitor of Fibronectin Fibrillogenesis Decreases Fibrosis in Murine Unilateral Ureteral Obstruction Model of Kidney Disease	56
3.1 Introduction	57
3.2 Materials and Methods	58
3.2.1 Preparation of PEGylated peptides	58
3.2.2 Microtiter Fibronectin Matrix Assembly Assays	58
3.2.2.1 Exogenous Plasma Fibronectin Matrix Assembly Assay	58
3.2.2.2 Endogenous (cellular) Fibronectin Assembly Assay	59
3.2.3 Unilateral Ureteral Obstruction Model	61
3.2.4 Histology and Immunostaining	62
3.2.5 Tissue Extraction and Immunoblotting	63
3.2.5.1 ECM and Lysate/membrane Fractions from Kidney Extracts	63
3.2.5.2 Antibody to FUD	64
3.2.6 Statistics	64
3.3 Results	65
3.3.1 Comparison of PEG-FUD with FUD as Inhibitors of Fibronectin Assembly <i>in vitro</i>	65


Example: Pawel Zbyszynski

ix

Chapter 5: Concluding Remarks and Future Research	133
5.1 Primary Findings and Conclusions	134
5.1.1 Synthesis and Characterization of PEG-FUD	135
5.1.2 In Vivo Evaluation of PEG-FUD in a Murine Model of Renal Fibrosis	136
5.1.3 Probing Subcutaneous Absorption of PEG-FUD	137
5.2 Future Research	139
5.2.1 Fibrosis Combinational Therapy using PEG-FUD and Rapamycin, an mTOR Inhibitor	139
5.2.2 PEG-FUD as an Anti-Cancer Therapeutic	141
5.2.2.1 Attenuating Primary Tumor Growth	141
5.2.2.2 Attenuating Fibrosis-linked Metastasis	142
5.2.2.3 Attenuating Ovarian Cancer Metastasis	143
5.3 Final Remarks	144
Bibliography	145


Other advice

- Communicate with advisor
- Getting started can be hardest part
- Set writing goals/feedback dates
- Pomodoro method can help
- Outlines can help
- "Hold your nose and type"
- For intro and conclusion chapters- focus on major points first
- Utilize existing writing (e.g. published)
- Grammar tools



What else can help this to not be you!

- Grad school workshops
- Utilize writing center (<https://writing.wisc.edu>)
- Dissertator group counseling (<https://www.uhs.wisc.edu/mental-health/group-counseling/schedule/>)
- Self care (exercise, meditation, yoga, eating well, etc.)
- Remember that you are not alone and seek comradery/help when needed



Remember the end goal!



PHOTO: KORIE MITCHELL/JESSACOLE PHOTOGRAPHY

<https://people.com/human-interest/eve-humphrey-dissertation-maternity-photo-shoot-florida/>